Skip to content

Shuttle Pharmaceuticals

1 viewer · 30d

Total raised

$10.0M

+$10.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $10.0M
ROUNDS
1
INVESTORS
47
FOUNDED
N/A
HQ
Gaithersburg, MD
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company in Gaithersburg, Maryland, founded in 2012 by faculty of the Georgetown University Medical Center and listed on Nasdaq as SHPH. It develops radiation sensitizers and related diagnostics intended to improve outcomes for cancer patients treated with radiation therapy. Its lead candidate, Ropidoxuridine (IPdR), received an FDA 'safe to proceed' letter in January 2024 and is enrolling patients in a Phase 2 trial in newly diagnosed IDH-wildtype, MGMT-unmethylated glioblastoma at sites including Georgetown, UNC, UVA and Miami Cancer Institute. The company also markets Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development.

What sets it apart

Rather than attacking tumors directly, its lead compound is designed to make cancer cells more sensitive to radiation therapy that patients already receive, and it holds FDA Orphan Drug Designation in glioblastoma.

Funding history

1 round
Equity+2Apr 30, 2026
Form D
+$10.0M$10.0M total

Latest SEC filings

via EDGAR · CIK 0001757499
Form D · Apr 30, 2026View on EDGAR

Products

1 tracked

Ropidoxuridine (IPdR)

Oncology drug candidate

An orally administered radiation-sensitizing drug candidate given alongside radiotherapy, currently in a Phase 2 clinical trial in newly diagnosed IDH-wildtype glioblastoma with an unmethylated MGMT promoter.

  • Oral radiation sensitizer used in combination with radiotherapy
  • FDA 'safe to proceed' letter received January 2024 for the Phase 2 study
  • FDA Orphan Drug Designation for glioblastoma
  • Phase 2 randomizes patients across 1,200 mg/day and 960 mg/day dose levels

Links

WebsiteLinkedInSEC EDGAR filings